Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

hormone therapy

, , ,

Orgovyx - The Newest Hormone Treatment (ADT) for Prostate Cancer

, , ,
Orgovyx - The Newest Hormone Treatment (ADT) for Prostate Cancer

HERO demonstrated that Orgovyx was superior to Lupron in maintaining castration from day 29 up to week 48. Orgovyx also showed an almost a five-fold reduction in the risk of subsequent major cardiac events, a concern for men on Lupron.

, ,

Bipolar Androgen Therapy Effective in Metastatic Castration-Resistant Prostate Cancer

, ,
Bipolar Androgen Therapy Effective in Metastatic Castration-Resistant Prostate Cancer

The authors concluded that “TRANSFORMER establishes meaningful clinical activity of BAT and supports additional study to determine its optimal clinical integration.”

,

FDA Approves An Oral Hormone Therapy (ADT) 

,
FDA Approves An Oral Hormone Therapy (ADT) 

The Food and Drug Administration has approved a new drug for men with advanced prostate cancer. The approval is for a first in kind hormone therapy (ADT) taken orally (by mouth) instead of the regular Lupron type injections we have been using.

Besides achieving and maintaining adequate levels of castration, Orgovyx was also superior to Lupron because it cut the incidence of serious heart events compared to Lupron.

Gold Guidestar Seal
Gold Transparency 2022